AlphaStocks
5.8
Consider Buy

AbbVie Inc. (ABBV)

Health Care / Biotechnology

S&P 500

$206.67

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#300out of 1126 in Health Care

Is AbbVie Inc. a Good Investment in 2026?

AbbVie Inc. (ABBV) scores 5.8 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates AbbVie Inc. as Strong (9/9). The Greenblatt Magic Formula model is the least favorable, rating it Neutral. AbbVie Inc. currently trades above its estimated fair value of $110, suggesting limited upside at current prices. AbbVie Inc. ranks #300 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E86.7ROE-143.0Market Cap366BDiv Yield3.2

Estimated Fair Value

$109.8788% above

Trading above estimated fair value. P/e of 87x implies high growth expectations. eps growth of -1% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

9/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Top half (rank 32%)

Frequently Asked Questions

Is AbbVie Inc. (ABBV) a good investment?
Based on AlphaStocks' composite analysis, AbbVie Inc. (ABBV) scores 5.8 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading above estimated fair value. P/e of 87x implies high growth expectations. eps growth of -1% may not justify the premium.
What is AbbVie Inc.'s Piotroski F-Score?
AbbVie Inc.'s Piotroski F-Score status is Strong. The raw score is 9/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ABBV overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $110, ABBV appears overvalued. The stock currently trades 88% above its estimated fair value. Trading above estimated fair value. P/e of 87x implies high growth expectations. eps growth of -1% may not justify the premium.
How does ABBV compare to other Health Care stocks?
AbbVie Inc. ranks #300 out of 1126 stocks in the Health Care sector, placing it in the top 27% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about ABBV?
AlphaStocks evaluates ABBV using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.8/10.

Similar Stocks

PARRFTIAZN

Compare ABBV with

ABBV vs PARRABBV vs FTIABBV vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer